康诺亚-B:CMG901全球III期临床获积极顶线结果,OS改善具统计学显著性

智通财经
Jul 28
【康诺亚-B:CMG901全球III期临床获积极顶线结果,OS改善具统计学显著性】康诺亚-B公告,公司与AstraZeneca合作的CMG901全球III期临床试验CLARITY-Gastric01取得积极顶线结果。与研究者选择的治疗方案相比,CMG901在二线及后线CLDN18.2阳性晚期胃癌患者中展现出具有统计学显著性且极具临床意义的总生存期改善。试验达到了三线及后线治疗OS双重主要终点及二线及后线治疗整体试验人群OS关键次要终点;PFS呈现改善趋势但未达统计学显著性。安全性特征与已知一致,未发现新安全信号。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10